← Leaderboards
Jeffrey A Kern
University Of Iowa
$3,718,885
Attributed
$5,769,803
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $638.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,769,803 · 4
By mechanism
U01$3,076,377 · 1
R01$2,278,613 · 2
R21$414,813 · 1
Top collaborators
- Mario Lacouture5 shared
- Donald Ym Leung5 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Robert Bruce Wallace$4,552,812
- Kevin L Legge$8,443,120
- Joseph Zabner$29,014,505
- John G Koland$438,449
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeIn VitroResponseSignal TransductionCancer TherapyEventAffectCytokineTargeted TreatmentBiologicalPathway InteractionsInflammatorySamplingNovel Therapeutic InterventionEarly IdentificationDoseEndocannabinoidsApplications GrantsCutaneousDermatologicEpidermal Growth FactorBiological MarkersAdverse EventAdrenal Cortex Hormones
Grant awards (14)
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$608,731
U01 · FY2024 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$613,843
U01 · FY2023 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$610,938
U01 · FY2022 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$604,257
U01 · FY2021 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$638,608
U01 · FY2020 · AR
Kinase Dependent Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer$177,432
R21 · FY2017 · CA · contact PI
Kinase Dependent Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer$237,381
R21 · FY2016 · CA · contact PI
NRG/HER Restoration of the Lung Epithelium After Injury$366,235
R01 · FY2008 · HL · contact PI
NRG/HER Restoration of the Lung Epithelium After Injury$366,235
R01 · FY2007 · HL · contact PI
NRG/HER Restoration of the Lung Epithelium After Injury$377,173
R01 · FY2006 · HL · contact PI
NRG/HER Restoration of the Lung Epithelium After Injury$359,000
R01 · FY2005 · HL
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT$274,917
R01 · FY2002 · HL
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT$274,035
R01 · FY2001 · HL
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT$261,018
R01 · FY2000 · HL